Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?

Subjects

Subjects :

Anaplastic Lymphoma Kinase
Carbazoles
Crizotinib
Humans
Piperidines
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Details

Language :

English

ISSN :

1569-8041

Volume :

29

Issue :

11

Database :

MEDLINE

Journal :

Annals of oncology : official journal of the European Society for Medical Oncology

Publication Type :

Editorial & Opinion

Accession number :

30239586

Full Text :

https://doi.org/10.1093/annonc/mdy415